TY - JOUR T1 - Investigation of <em>Survivin</em> Gene Polymorphism and Serum Survivin Levels in Patients with Brain Tumors JF - Anticancer Research JO - Anticancer Res SP - 5991 LP - 5998 DO - 10.21873/anticanres.12947 VL - 38 IS - 10 AU - DIDEM KAFADAR AU - ILHAN YAYLIM AU - ALI METIN KAFADAR AU - CANAN CACINA AU - ARZU ERGEN AU - MEHMET YASAR KAYNAR AU - TURGAY ISBIR Y1 - 2018/10/01 UR - http://ar.iiarjournals.org/content/38/10/5991.abstract N2 - Background/Aim: The single nucleotide polymorphism -31C/G identified in the survivin gene promoter seems to be associated with over-expression of survivin, an anti-apoptotic protein. In gliomas, increased survivin expression correlated with decreased survival. The aim of the study was to investigate whether survivin gene polymorphism associates with benign and malignant brain tumors and whether it affects survivin serum levels. Patients and Methods: Survivin polymorphism -31C&gt;G was genotyped in 82 patients with brain tumors and 65 healthy controls by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and survivin levels were evaluated by enzyme-linked immuno sorbent assay (ELISA) in patients and controls. Results: Serum survivin levels in patients with malignant tumors were higher than patients with benign tumors (p&lt;0.001). Survivin levels in patients with malignant glial tumors and the frequency of the GG genotype were higher than in patients with benign tumors (p=0.04) and controls (p=0.05). The prevelance of the survivin gene promoter polymorphism -31C&gt;G did not differ between patients and controls. Conclusion: Survivin promoter -31C&gt;G gene polymorphism seems to be associated with serum survivin levels in brain tumors of different grades and histologies. ER -